
Imexon
CAS No. 59643-91-3
Imexon( Amplimexon | BM 06002 )
Catalog No. M15211 CAS No. 59643-91-3
A 2-cyanoaziridine derivative with antitumor activity in some types of cancer.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 1233 | In Stock |
![]() ![]() |
50MG | 2502 | In Stock |
![]() ![]() |
100MG | 3330 | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameImexon
-
NoteResearch use only, not for human use.
-
Brief DescriptionA 2-cyanoaziridine derivative with antitumor activity in some types of cancer.
-
DescriptionA 2-cyanoaziridine derivative with antitumor activity in some types of cancer, including pancreatic, lung, breast, prostate, melanoma, and multiple myeloma; induces mitochondrial oxidation and induces apoptosis via a pathway involving cleaved caspase-3, caspase-9, and/or caspase-8; an apoptosis inducer agent.Blood Cancer Phase 2 Clinical.
-
In VitroImexon (BM 06002) induces oxidative stress in the ER, activates an ER stress response. Imexon (BM 06002) does not significantly alter the levels of eIF2B5, however there is a dose-dependent increase in the phosphorylation of eIF2alpha, as well as an increase in the levels of GTP exchange protein eIF2B2 in MiaPaCa-2, Panc-1, and BxPC3 cells. Imexon (BM 06002) induces single-stranded breaks in the human A375 melanoma cells but only significantly at the highest concentrations for each agent compared to controls. Imexon plus DTIC cytotoxicity is additive. Imexon (BM 06002) show inhibitory activities against MiaPaCa-2, Panc-1 and BxPC3, with IC50s of 275.5 ± 54.2, 147.4 ± 4.7 and 355.7 ± 114.7 μM.
-
In VivoImexon (BM 06002) in combination with DTIC results in an increase in the peak plasma imexon level in non-tumor-bearing mice. The combination of both drugs increases plasma imexon AUC by 22% (p=0.026). Imexon (BM 06002) (100 mg/kg/day, i.v.) treatment decreases the body weight of SCID mice bearing human A375 melanoma tumors, but there is no significant difference in tumor growth. Imexon (BM 06002) (100 mg/kg) in combination with GEM shows synergistic inhibition of Panc-1 tumor growth in SCID mice.
-
SynonymsAmplimexon | BM 06002
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis
-
Research AreaCancer
-
IndicationBlood cancer
Chemical Information
-
CAS Number59643-91-3
-
Formula Weight111.104
-
Molecular FormulaC4H5N3O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 62.5 mg/mL (562.56 mM)
-
SMILESO=C1N2CC2C(N)=N1
-
Chemical Name4-Amino-1,3-diazabicyclo[3.1.0]hex-3-en-2-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ziegler AE, et al. Exp Pathol (Jena). 1977;14(6):321-7.
2. Hersh EM, et al. J Natl Cancer Inst. 1992 Aug 19;84(16):1238-44.
3. Baker AF, et al. Clin Cancer Res. 2007 Jun 1;13(11):3388-94.
molnova catalog



related products
-
MKC-1
MKC-1 is an orally bioavailable, small-molecule, bisindolylmaleimide cell cycle inhibitor with potential antineoplastic activity. MKC-1 and its metabolites inhibit tubulin polymerization, blocking the formation of the mitotic spindle.
-
3-?O-?Acetyloleanoli...
3-O-acetyloleanolic acid dose-dependently inhibited the viability of HCT-116 cells. Apoptosis was characterized by detection of cell surface annexin V and sub-G1 apoptotic cell populations.
-
3-Deoxyaconitine
3-?Deoxyaconitine is a derivative of Aconitine (A189875), which activates tetrodotoxin-sensitive Na+ channels, inducing presynaptic depolarization.